Page last updated: 2024-09-03

reboxetine and Depression, Endogenous

reboxetine has been researched along with Depression, Endogenous in 99 studies

Research

Studies (99)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	23 (23.23)	18.2507
2000's	58 (58.59)	29.6817
2010's	18 (18.18)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Lenda, T; Pałucha-Poniewiera, A; Pilc, A; Podkowa, K	1
Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C	1
Kulkarni, J; Naidu, C	1
Taylor, D; Whiskey, E	1
Cowen, P; Crawford, AA; Lewis, G; Lewis, S; Nutt, D; O'Donovan, MC; Peters, TJ; Wiles, N	1
Filipek, B; Olczyk, A; Pytka, K; Rapacz, A; Sapa, J; Waszkielewicz, A; Zygmunt, M	1
Ampuero, E; Cavada, G; Diaz-Veliz, G; Luarte, A; Rubio, FJ; Santibañez, M; Toledo, J; Varas-Godoy, M; Wyneken, U	1
Beltran, E; Domínguez-Andrés, J; Erburu, M; Mai, A; Muñoz-Cobo, I; Puerta, E; Suzuki, T; Tordera, RM; Valente, S	1
Chuluunkhuu, G; Kamae, I; Nakahara, N; Yanagisawa, S	1
Andreasen, JT; Redrobe, JP	1
Brunnauer, A; David, I; Fric, M; Hermisson, I; Laux, G; Möller, HJ	1
Stafford, N	1
Ayres, R; Cowen, PJ; Favaron, E; Goodwin, GM; Harmer, CJ; Massey-Chase, R; O'Sullivan, U; Reinecke, A	1
Thase, ME	1
Cowen, PJ; Harmer, CJ; McCabe, C; Mishor, Z	1
Koch, K; Reichenbach, JR; Sauer, H; Schachtzabel, C; Schlösser, RG; Sobanski, T; Wagner, G	1
Krishnadas, R	1
Turner, EH	1
Cowen, P; Craddock, N; Grozeva, D; Ikeda, M; Lewis, G; Mason, V; Mulligan, J; Nutt, D; O'Donovan, MC; Peters, TJ; Sharp, D; Tallon, D; Thomas, L; Wiles, N	1
Aldenhoff, J; Göder, R; Huchzermeier, C; Koch, J; Kropp, C; Palaschewski, M; Seeck-Hirschner, M; Stingele, K	1
Arolt, V; Cerovecki, A; Dehning, S; Müller, N; Musil, R; Riedel, M; Schwarz, MJ; Spellmann, I	1
Cowen, PJ; Lewis, G; Mason, V; Mulligan, J; Nutt, D; O'Donovan, MC; Peters, TJ; Sharp, D; Tallon, D; Thomas, L; Wiles, NJ	1
Bould, H; Cowen, P; Lewis, G; Nutt, DJ; Peters, TJ; Potokar, J; Wiles, N	1
First, M; Gil-Ad, I; Novak, N; Taler, M; Tarasenko, I; Weizman, A	1
Cohen, NL; Kennedy, SH; Lam, RW; Wan, DD	1
Aguglia, E; Amore, M; Delgado, PL; Gastpar, M; Hawley, C; Hirschfeld, RM; Kasper, S; Linden, M; Massana, J; Mendlewicz, J; Möller, HJ; Montgomery, SA; Nemeroff, CB; Saiz, J; Such, P; Torta, R; Versiani, M	1
Ferguson, JM; Schwartz, GE; Wesnes, KA	1
Chue, P; Cohen, NL; Craigen, G; Kennedy, SH; Lam, RW; McIntyre, RS; Rosenbluth, M; Sokolov, ST	1
Bodie, B; Herman, JP; Renda, A	1
Brown, MT; Clayton, AH; Ferguson, JM; Filipiak-Reisner, JK; Schwartz, GE; Zajecka, J	1
Carvalhal, AS; Correa, J; de Abreu, PB; Kapczinski, F; Spode, A	1
Cowen, PJ; Goodwin, GM; Harmer, CJ; Hill, SA; Taylor, MJ	1
Abdelrahman, N; Da'as, N; Kleinman, Y; Rund, D	1
Khazaal, Y; Zullino, DF	1
Page, ME	1
Alvano, A; Chiechio, S; Malaguarnera, M; Nicoletti, G; Raffaele, R; Rampello, L; Vecchio, I	1
Brown, MT; Filipiak-Reisner, JK; Fleishaker, JC; Hajós, M; Wong, EH	1
Biancosino, B; Grassi, L; Marmai, L; Righi, R	1
Alamo, C; López-Muñoz, F; Rubio, G; San, L	1
Cowen, PJ; Goodwin, GM; Harmer, CJ; Shelley, NC	1
Abrams, M; Cook, IA; Krell, HV; Leuchter, AF; Morgan, M	1
Bertolín-Guillén, JM; Climent-Díaz, B; Navarré-Gimeno, A	1
Aragona, M; Bancheri, L; Conte, A; Inghilleri, M; Perinelli, D; Pizzimenti, A; Tarsitani, L	1
Akgöz, S; Akkaya, C; Eker, SS; Kirli, S; Sarandöl, A	1
Leon, AC; Nelson, JC; Portera, L	1
Arolt, V; Cerovecki, A; Dehning, S; Douhe, A; Goldstein-Müller, B; Hetzel, G; Kleindienst, N; Maino, K; Möller, HJ; Müller, N; Riedel, M; Schwarz, MJ; Spellmann, I	1
Berlanga, C; Flores-Ramos, M	1
Butler, R; Carney, S; Cipriani, A; Geddes, J; Hatcher, S; Price, J; Von Korff, M	1
Knobler, H; Schattner, A; Zornitzki, T	1
Castrén, E; Chao, MV; Domenici, E; Hendolin, P; Kankaanpää, A; Männistö, PT; Mijatovic, J; Piepponen, P; Rantamäki, T	1
Bajbouj, M; Danker-Hopfe, H; Gallinat, J; Hellen, F; Lang, UE; Lisanby, SH; Neu, P; Vesper, J	1
Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ	1
Montgomery, SA	4
Leonard, BE	1
Hindmarch, I	1
Berzewski, H; Gagiano, CA; Van Moffaert, M	1
Bosc, M; Dubini, A; Polin, V	3
Mucci, M	1
Montgomery, SA; Schatzberg, AF	1
Burrows, GD; Maguire, KP; Norman, TR	1
Massana, J	1
Charney, DS	1
Dantchev, N; Widlöcher, DJ	1
Schatzberg, AF	2
Burrows, GD; Massana, J; Möller, HJ; Montenegro, RM	1
Healy, D; Healy, H	1
Arnaud-Castiglioni, R; Gaszner, P; Mehilane, L; Versiani, M	1
Eichhorn, T; Krieg, JC; Schreiber, W	1
Bercoff, E; Chiu, E; Katona, C; Tack, P; Versiani, M; Woelk, H	1
Franzoni, S; Ranieri, P; Trabucchi, M	1
Gorman, JM; Sullivan, G	1
Fava, M	1
Kent, JM	1
Hirschfeld, RM	1
Amara, SG; Bonsignori, A; Carfagna, N; Franklin, S; Hoffmann, WP; Hyslop, DK; McArthur, RA; Piercey, MF; Porsolt, RD; Sonders, MS; Tinholt, PM; Wong, EH	1
Fleishaker, JC; Pellizzoni, C; Poggesi, I	1
Nemeroff, CB	1
Aguglia, E	1
Arcelus, A; Barr, CE; Birnbaum, H; Greenberg, P; Rowland, C; Venditti, LN; Williamson, T	1
Doraiswamy, PM; Scates, AC	1
Michael, A; O'Flynn, R	1
Lemke, MR	2
Harkin, A; Kelly, JP; Leonard, BE; Nally, R	1
Devarajan, S; Dursun, SM	1
el Giamal, N; Hilger, E; Kasper, S	1
Ferguson, JM; Mendels, J; Schwart, GE	1
Aschauer, N; Kasper, S; Moffat, R; Pezawas, L; Stamenkovic, M	1

Reviews

24 review(s) available for reboxetine and Depression, Endogenous

Article	Year
A review of the adverse effects and safety of noradrenergic antidepressants. Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:8 Topics: Antidepressive Agents; Depressive Disorder; Drug-Related Side Effects and Adverse Reactions; Humans; Morpholines; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors	2013
Combining antidepressants for treatment-resistant depression: a review. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:8 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Humans; Mianserin; Monoamine Oxidase Inhibitors; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2002
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:9 Topics: Antidepressive Agents; Congresses as Topic; Cyclopropanes; Decision Trees; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lithium; Mianserin; Milnacipran; Mirtazapine; Morpholines; Practice Patterns, Physicians'; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2002
The promises and pitfalls of reboxetine. CNS drug reviews, 2003,Winter, Volume: 9, Issue:4 Topics: Animals; Antidepressive Agents; Brain; Clinical Trials as Topic; Depressive Disorder; Humans; Mice; Microdialysis; Morpholines; Norepinephrine; Physical Exertion; Reboxetine; Swimming; Treatment Outcome	2003
The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS drug reviews, 2004,Spring, Volume: 10, Issue:1 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Cognition; Controlled Clinical Trials as Topic; Depressive Disorder; Drug Tolerance; Humans; In Vitro Techniques; Morpholines; Norepinephrine; Reboxetine; Receptors, Adrenergic; Serotonin; Time	2004
Depression in adults. Clinical evidence, 2006, Issue:15 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder; Electroconvulsive Therapy; Humans; Hypericum; Monoamine Oxidase Inhibitors; Morpholines; Phytotherapy; Plant Preparations; Psychotherapy; Reboxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride	2006
Is there a role for a pure noradrenergic drug in the treatment of depression? European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Humans; Methoxyhydroxyphenylglycol; Morpholines; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin	1997
Noradrenaline in basic models of depression. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Depressive Disorder; Disease Models, Animal; Humans; Morpholines; Olfactory Bulb; Reboxetine; Receptors, Adrenergic; Stress, Psychological	1997
The effects of antidepressants on psychomotor function with particular reference to reboxetine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Humans; Morpholines; Psychomotor Performance; Reboxetine; Selective Serotonin Reuptake Inhibitors	1997
Reboxetine: additional benefits to the depressed patient. Journal of psychopharmacology (Oxford, England), 1997, Volume: 11, Issue:4 Suppl Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Morpholines; Norepinephrine; Reboxetine	1997
Reboxetine: a review of antidepressant tolerability. Journal of psychopharmacology (Oxford, England), 1997, Volume: 11, Issue:4 Suppl Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine	1997
Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Age Factors; Aged; Clinical Trials as Topic; Depressive Disorder; Drug Administration Schedule; Dysthymic Disorder; Humans; Middle Aged; Morpholines; Multicenter Studies as Topic; Norepinephrine; Reboxetine; Treatment Outcome	1998
Monoamine dysfunction and the pathophysiology and treatment of depression. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Carrier Proteins; Catecholamines; Cocaine; Depressive Disorder; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Neuropeptides; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon; Tryptophan	1998
Chairman's overview. The place of reboxetine in antidepressant therapy. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Aged; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Morpholines; Reboxetine; Severity of Illness Index; Social Adjustment; Treatment Outcome	1998
Antidepressant effectiveness in severe depression and melancholia. The Journal of clinical psychiatry, 1999, Volume: 60 Suppl 4 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Humans; Morpholines; Reboxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride	1999
The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing? Journal of affective disorders, 1998, Volume: 51, Issue:3 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; Morpholines; Placebos; Quality of Life; Reboxetine; Social Adjustment; Surveys and Questionnaires; Temperament; Treatment Outcome	1998
Predicting response: noradrenaline reuptake inhibition. International clinical psychopharmacology, 1999, Volume: 14 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Animals; Depressive Disorder; Humans; Morpholines; Norepinephrine; Reboxetine	1999
Noradrenergic approaches to antidepressant therapy. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 1 Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder; Humans; Mianserin; Mirtazapine; Morpholines; Norepinephrine; Reboxetine; Receptors, Adrenergic; Selective Serotonin Reuptake Inhibitors	2000
New approaches to the treatment of refractory depression. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 1 Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Drug Therapy, Combination; Humans; Lithium; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Pindolol; Piperazines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Triazoles; Triiodothyronine	2000
SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet (London, England), 2000, Mar-11, Volume: 355, Issue:9207 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder; Humans; Mianserin; Mirtazapine; Morpholines; Piperazines; Reboxetine; Structure-Activity Relationship; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride	2000
History and evolution of the monoamine hypothesis of depression. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 6 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Drug Industry; History, 20th Century; Humans; Imipramine; Morpholines; Norepinephrine; Reboxetine; Receptors, Biogenic Amine; Serotonin	2000
Clinical efficacy of reboxetine in major depression. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 10 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Imipramine; Morpholines; Norepinephrine; Panic Disorder; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2000
Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. The Annals of pharmacotherapy, 2000, Volume: 34, Issue:11 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Biological Availability; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Half-Life; Humans; Middle Aged; Morpholines; Reboxetine; Tissue Distribution	2000
Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert opinion on pharmacotherapy, 2000, Volume: 1, Issue:4 Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder; Humans; Middle Aged; Morpholines; Norepinephrine; Pharmacokinetics; Reboxetine; Social Behavior	2000

Trials

37 trial(s) available for reboxetine and Depression, Endogenous

Article	Year
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology, 2014, Volume: 231, Issue:15 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dizziness; Female; Follow-Up Studies; Humans; Male; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Refusal	2014
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:12 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Attention; Automobile Driving; Computer Simulation; Depressive Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Psychomotor Performance; Reaction Time; Reboxetine	2008
Effect of acute antidepressant administration on negative affective bias in depressed patients. The American journal of psychiatry, 2009, Volume: 166, Issue:10 Topics: Adolescent; Adult; Affect; Antidepressive Agents; Anxiety Disorders; Depression; Depressive Disorder; Emotions; Facial Expression; Female; Humans; Male; Memory; Middle Aged; Morpholines; Personality; Personality Inventory; Reboxetine; Recognition, Psychology; Visual Perception	2009
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biological psychiatry, 2010, Mar-01, Volume: 67, Issue:5 Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anxiety Disorders; Citalopram; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Morpholines; Nerve Net; Reboxetine; Reward; Selective Serotonin Reuptake Inhibitors; Young Adult	2010
Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. The British journal of psychiatry : the journal of mental science, 2011, Volume: 198, Issue:6 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Homozygote; Humans; Life Change Events; Male; Middle Aged; Morpholines; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Reboxetine; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; United Kingdom; Young Adult	2011
Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression. Journal of sleep research, 2011, Volume: 20, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Depressive Disorder; Female; Humans; Male; Memory; Morpholines; Neuropsychological Tests; Polysomnography; Reboxetine; Sleep; Sleep, REM; Young Adult	2011
Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment. Journal of affective disorders, 2011, Volume: 134, Issue:1-3 Topics: Adult; Aged; Antidepressive Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Depression; Depressive Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Psychological Tests; Pyrazoles; Reboxetine; Sulfonamides; Transforming Growth Factor beta; Young Adult	2011
Severity of depression and response to antidepressants: GENPOD randomised controlled trial. The British journal of psychiatry : the journal of mental science, 2012, Volume: 200, Issue:2 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Citalopram; Depressive Disorder; Female; Humans; Intention to Treat Analysis; International Classification of Diseases; Linear Models; Male; Middle Aged; Morpholines; Primary Health Care; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United Kingdom; Young Adult	2012
Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:5 Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Fatigue; Female; Follow-Up Studies; Humans; Male; Morpholines; Reboxetine; Severity of Illness Index; Treatment Outcome	2012
Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International clinical psychopharmacology, 2003, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2003
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. International clinical psychopharmacology, 2003, Volume: 18, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Patient Compliance; Patient Satisfaction; Reboxetine; Sexual Dysfunction, Physiological	2003
An open trial of reboxetine in HIV-seropositive outpatients with major depressive disorder. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:4 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Antidepressive Agents; Comorbidity; Depressive Disorder; Female; HIV Seropositivity; Humans; Hyperhidrosis; Male; Middle Aged; Morpholines; Nausea; Psychiatric Status Rating Scales; Reboxetine; Sleep Initiation and Maintenance Disorders; Treatment Outcome	2003
Toward a neuropsychological theory of antidepressant drug action: increase in positive emotional bias after potentiation of norepinephrine activity. The American journal of psychiatry, 2003, Volume: 160, Issue:5 Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Depressive Disorder; Discrimination, Psychological; Double-Blind Method; Emotions; Facial Expression; Female; Happiness; Humans; Male; Memory; Middle Aged; Models, Biological; Models, Psychological; Morpholines; Negativism; Neuropharmacology; Neuropsychological Tests; Personality; Reboxetine	2003
Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology, 2004, Volume: 173, Issue:1-2 Topics: Adrenergic Uptake Inhibitors; Aged; Analysis of Variance; Case-Control Studies; Citalopram; Depressive Disorder; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Morpholines; Predictive Value of Tests; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Stroke; Treatment Outcome	2004
Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:4 Topics: Adaptation, Psychological; Adult; Aged; Antidepressive Agents; Breast Neoplasms; Depressive Disorder; Drug Administration Schedule; Female; Humans; Middle Aged; Morpholines; Personality Inventory; Psychiatric Status Rating Scales; Quality of Life; Reboxetine; Severity of Illness Index; Treatment Outcome	2004
Reboxetine adjunct for partial or nonresponders to antidepressant treatment. Journal of affective disorders, 2004, Volume: 81, Issue:1 Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Dysthymic Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2004
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. The American journal of psychiatry, 2004, Volume: 161, Issue:7 Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depressive Disorder; Double-Blind Method; Facial Expression; Fear; Female; Hostility; Humans; Male; Memory; Morpholines; Placebos; Reboxetine; Recognition, Psychology; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Social Perception; Surveys and Questionnaires; Visual Perception	2004
Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:9 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Attitude to Health; Cross-Over Studies; Depressive Disorder; Drugs, Investigational; Female; Health Status; Humans; Male; Middle Aged; Morpholines; Placebos; Psychiatric Status Rating Scales; Reboxetine; Regression Analysis; Single-Blind Method; Treatment Outcome	2004
Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. European journal of pain (London, England), 2005, Volume: 9, Issue:1 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Analgesics; Central Nervous System; Citalopram; Depressive Disorder; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Pain Measurement; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Somatoform Disorders; Treatment Outcome	2005
[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder]. Turk psikiyatri dergisi = Turkish journal of psychiatry, 2005,Fall, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Depressive Disorder; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2005
Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11 Topics: Adrenergic Uptake Inhibitors; Adult; Anxiety Disorders; Depression; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Libido; Male; Morpholines; Norepinephrine; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Wake Disorders; Treatment Outcome	2005
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular psychiatry, 2006, Volume: 11, Issue:7 Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Dinoprostone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-6; Lorazepam; Male; Middle Aged; Morpholines; Patient Dropouts; Pilot Projects; Psychological Tests; Pyrazoles; Reboxetine; Serotonin; Severity of Illness Index; Sulfonamides	2006
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of affective disorders, 2006, Volume: 95, Issue:1-3 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Citalopram; Depressive Disorder; Double-Blind Method; Female; Gonadal Hormones; Humans; Male; Morpholines; Premenopause; Reboxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin; Sex Factors	2006
Motor cortex excitability after vagus nerve stimulation in major depression. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Adult; Benzodiazepines; Citalopram; Clomipramine; Clozapine; Depressive Disorder; Doxepin; Drug Therapy, Combination; Electric Stimulation; Female; Humans; Lamotrigine; Lithium Carbonate; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Motor Cortex; Neural Conduction; Neural Inhibition; Olanzapine; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Tranylcypromine; Triazines; Vagus Nerve; Valproic Acid	2007
Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Depressive Disorder; Double-Blind Method; Electrocardiography; Female; Headache; Humans; Imipramine; Male; Middle Aged; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Xerostomia	1997
Do noradrenaline and serotonin differentially affect social motivation and behaviour? European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Behavior	1997
Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1997, Volume: 7 Suppl 1 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Social Behavior; Surveys and Questionnaires	1997
Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning. Journal of psychopharmacology (Oxford, England), 1997, Volume: 11, Issue:4 Suppl Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Behavior	1997
Reboxetine versus fluoxetine: an overview of efficacy and tolerability. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Morpholines; Motivation; Placebos; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Self Concept; Severity of Illness Index; Treatment Outcome	1998
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. International clinical psychopharmacology, 1999, Volume: 14, Issue:2 Topics: Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Reboxetine	1999
Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder; Double-Blind Method; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Morpholines; Norepinephrine; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Reboxetine; Secondary Prevention; Treatment Outcome	1999
Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. Journal of affective disorders, 1999, Volume: 55, Issue:2-3 Topics: Aged; Aging; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; Female; Geriatric Psychiatry; Humans; Hypotension; Imipramine; Male; Morpholines; Reboxetine; Treatment Outcome	1999
Pharmacokinetics of reboxetine in elderly patients with depressive disorders. International journal of clinical pharmacology and therapeutics, 2000, Volume: 38, Issue:5 Topics: Adrenergic Uptake Inhibitors; Aged; Aged, 80 and over; Area Under Curve; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Morpholines; Reboxetine	2000
Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study. International journal of geriatric psychiatry, 2000, Volume: 15, Issue:9 Topics: Aged; Antidepressive Agents; Depressive Disorder; Female; Geriatric Psychiatry; Headache; Humans; Male; Morpholines; Nausea; Quality of Life; Reboxetine; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome	2000
Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms. Psychopharmacology, 2001, Volume: 153, Issue:4 Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Cyclohexanols; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Venlafaxine Hydrochloride	2001
Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. International clinical psychopharmacology, 2002, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Sleep Initiation and Maintenance Disorders	2002
Effect of reboxetine on depression in Parkinson's disease patients. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:4 Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Parkinson Disease; Personality Inventory; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Treatment Outcome	2002

Other Studies

38 other study(ies) available for reboxetine and Depression, Endogenous

Article	Year
The involvement of monoaminergic neurotransmission in the antidepressant-like action of scopolamine in the tail suspension test. Progress in neuro-psychopharmacology & biological psychiatry, 2017, 10-03, Volume: 79, Issue:Pt B Topics: alpha-Methyltyrosine; Animals; Antidepressive Agents; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Membrane Transport Modulators; Mice, Inbred C57BL; Morpholines; Motor Activity; Norepinephrine; Reboxetine; Scopolamine; Serotonin	2017
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ open, 2017, Aug-03, Volume: 7, Issue:8 Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome	2017
Psychosis induced by antidepressant treatment with reboxetine. The Australian and New Zealand journal of psychiatry, 2019, Volume: 53, Issue:12 Topics: Antidepressive Agents; Depressive Disorder; Female; Humans; Middle Aged; Psychoses, Substance-Induced; Reboxetine	2019
Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system. Pharmacological reports : PR, 2015, Volume: 67, Issue:1 Topics: Animals; Antidepressive Agents; Bupropion; Depressive Disorder; Fenclonine; Fluoxetine; Male; Mice; Morpholines; Motor Activity; Piperazines; Postural Balance; Reboxetine; Serotonin; Serotonin Agents; Swimming; Xanthones	2015
Two Chronic Stress Models Based on Movement Restriction in Rats Respond Selectively to Antidepressant Drugs: Aldolase C As a Potential Biomarker. The international journal of neuropsychopharmacology, 2015, Mar-26, Volume: 18, Issue:10 Topics: Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Disease Models, Animal; Fluoxetine; Fructose-Bisphosphate Aldolase; Green Fluorescent Proteins; Male; Morpholines; Rats, Sprague-Dawley; Reboxetine; Restraint, Physical; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Stress, Psychological	2015
Chronic stress and antidepressant induced changes in Hdac5 and Sirt2 affect synaptic plasticity. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015, Volume: 25, Issue:11 Topics: Adult; Animals; Antidepressive Agents; Chronic Disease; Depressive Disorder; Fluoxetine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imipramine; Male; Mice, Inbred C57BL; Middle Aged; Morpholines; Neuronal Plasticity; Prefrontal Cortex; Reboxetine; RNA, Messenger; Sirtuins; Stress, Psychological	2015
The efficacy of reboxetine as an antidepressant, a meta-analysis of both continuous (mean HAM-D score) and dichotomous (response rate) outcomes. The Kobe journal of medical sciences, 2008, Jul-18, Volume: 54, Issue:2 Topics: Analysis of Variance; Antidepressive Agents; Depressive Disorder; Humans; Meta-Analysis as Topic; Morpholines; Odds Ratio; Placebos; Reboxetine; Treatment Outcome	2008
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behavioural brain research, 2009, Jan-30, Volume: 197, Issue:1 Topics: Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depressive Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Mecamylamine; Mice; Morpholines; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Norepinephrine; Reboxetine; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Serotonin	2009
German agency refuses to rule on drug's benefits until Pfizer discloses all trial results. BMJ (Clinical research ed.), 2009, Jun-22, Volume: 338 Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Industry; Germany; Humans; Morpholines; Reboxetine; Scientific Misconduct	2009
Rapid improvement in affective information processing after acute administration of reboxetine. The American journal of psychiatry, 2009, Volume: 166, Issue:10 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Brain Stem; Cognition; Depressive Disorder; Emotions; Humans; Morpholines; Psychotherapy; Reboxetine; Time Factors; Treatment Outcome	2009
Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression. Journal of psychiatry & neuroscience : JPN, 2010, Volume: 35, Issue:4 Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Brain; Citalopram; Cognition; Depressive Disorder; Electroencephalography; Evoked Potentials; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Morpholines; Neuropsychological Tests; Oxygen; Predictive Value of Tests; Psychiatric Status Rating Scales; Psychomotor Performance; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult	2010
Reboxetine in depression. NICE guidance differs, so where next? BMJ (Clinical research ed.), 2010, Nov-16, Volume: 341 Topics: Antidepressive Agents; Depressive Disorder; Humans; Meta-Analysis as Topic; Morpholines; Practice Guidelines as Topic; Reboxetine	2010
Reboxetine in depression. All the relevant data? BMJ (Clinical research ed.), 2010, Nov-16, Volume: 341 Topics: Antidepressive Agents; Depressive Disorder; Humans; Morpholines; Reboxetine; Research Design; United States; United States Food and Drug Administration	2010
The effects of reboxetine treatment on depression-like behavior, brain neurotrophins, and ERK expression in rats exposed to chronic mild stress. Journal of molecular neuroscience : MN, 2013, Volume: 50, Issue:1 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder; Dietary Sucrose; Extracellular Signal-Regulated MAP Kinases; Food Preferences; Gene Expression; Male; Maze Learning; Morpholines; Phosphorylation; Rats; Rats, Sprague-Dawley; Reboxetine; Receptor, trkB; Stress, Psychological; Weight Gain	2013
[New antidepressive drug with good tolerance. Patients function in daily life]. MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38 Topics: Activities of Daily Living; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Germany; Humans; Morpholines; Reboxetine	2002
Reboxetine: a preliminary report on its use through the Special Access Program. Journal of psychiatry & neuroscience : JPN, 2002, Volume: 27, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Canada; Depressive Disorder; Female; Health Services Accessibility; Humans; Male; Middle Aged; Morpholines; Primary Health Care; Reboxetine; Retrospective Studies	2002
Norepinephrine-gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. Biological psychiatry, 2003, Jan-15, Volume: 53, Issue:2 Topics: Analysis of Variance; Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Limbic System; Male; Morpholines; Neurons; Phenylpropanolamine; Rats; Rats, Sprague-Dawley; Reboxetine; Stress, Physiological	2003
Hyponatremia associated with the initiation of reboxetine therapy. European journal of clinical pharmacology, 2003, Volume: 59, Issue:2 Topics: Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Reboxetine	2003
Depersonalization-derealization syndrome induced by reboxetine. Swiss medical weekly, 2003, Jul-12, Volume: 133, Issue:27-28 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depersonalization; Depressive Disorder; Female; Humans; Middle Aged; Morpholines; Reboxetine	2003
Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine. European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:7 Topics: Cyclohexanols; Depressive Disorder; Emergency Medical Services; Humans; Male; Maprotiline; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Venlafaxine Hydrochloride	2004
[Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline]. MMW Fortschritte der Medizin, 2004, Jul-08, Volume: 146, Issue:27-28 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Attention; Brain; Depressive Disorder; Humans; Morpholines; Motivation; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors	2004
Reboxetine treatment and pseudopheochromocytoma. QJM : monthly journal of the Association of Physicians, 2007, Volume: 100, Issue:1 Topics: Adrenal Gland Neoplasms; Antidepressive Agents; Catecholamines; Depressive Disorder; Humans; Male; Middle Aged; Morpholines; Pheochromocytoma; Reboxetine	2007
Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:10 Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Binding Sites; Brain; Brain Chemistry; Brain-Derived Neurotrophic Factor; Citalopram; Cyclic AMP Response Element-Binding Protein; Depressive Disorder; Gyrus Cinguli; Hippocampus; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Morpholines; Phospholipase C gamma; Phosphorylation; Reboxetine; Receptor, trkB; Selective Serotonin Reuptake Inhibitors; Signal Transduction; Up-Regulation	2007
Restless legs syndrome as side effect of second generation antidepressants. Journal of psychiatric research, 2008, Volume: 43, Issue:1 Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Prospective Studies; Reboxetine; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors	2008
Introduction. Reboxetine: a new selective antidepressant for the treatment of depression. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Humans; Morpholines; Norepinephrine; Reboxetine; Treatment Outcome	1998
The measurement of retardation in depression. The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 14 Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Motor Activity; Psychiatric Status Rating Scales; Psychometrics; Psychomotor Agitation; Psychomotor Disorders; Psychomotor Performance; Reboxetine; Speech	1998
The role of norepinephrine in the treatment of depression. The Journal of clinical psychiatry, 1999, Volume: 60, Issue:9 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Humans; Morpholines; Norepinephrine; Placebos; Reboxetine; Selective Serotonin Reuptake Inhibitors	1999
Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition. Journal of neurology, neurosurgery, and psychiatry, 1999, Volume: 67, Issue:4 Topics: Adrenergic Uptake Inhibitors; Depressive Disorder; Female; Humans; Middle Aged; Morpholines; Reboxetine; Tetrabenazine	1999
Reboxetine and hyponatremia. The New England journal of medicine, 2000, Jan-20, Volume: 342, Issue:3 Topics: Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents; Depressive Disorder; Humans; Hyponatremia; Male; Morpholines; Reboxetine	2000
Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biological psychiatry, 2000, May-01, Volume: 47, Issue:9 Topics: Adrenergic Uptake Inhibitors; Animals; Brain Chemistry; Carrier Proteins; Cells, Cultured; Conditioning, Operant; Depressive Disorder; Dogs; Dose-Response Relationship, Drug; Electrophysiology; Fluvoxamine; Male; Mice; Morpholines; Norepinephrine; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reboxetine; Receptors, Adrenergic; Reinforcement Schedule; Selective Serotonin Reuptake Inhibitors; Synaptosomes	2000
Introduction. Norepinephrine: neurotransmitter for the millennium. The Journal of clinical psychiatry, 2000, Volume: 61 Suppl 10 Topics: Adrenergic Uptake Inhibitors; Depressive Disorder; Humans; Morpholines; Norepinephrine; Reboxetine; Synaptic Transmission	2000
Depression. Five new treatments. Harvard health letter, 2000, Volume: 25, Issue:11 Topics: Antidepressive Agents; Depression; Depressive Disorder; Electric Stimulation Therapy; Humans; Hydrocortisone; Magnetics; Morpholines; Reboxetine; Substance P; Vagus Nerve	2000
The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. International clinical psychopharmacology, 2000, Volume: 15, Issue:5 Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder; Female; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Social Behavior; Treatment Outcome	2000
Novel antidepressant strategies to optimize outcome. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:9 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Morpholines; Norepinephrine; Personality Inventory; Reboxetine; Severity of Illness Index; Social Adjustment; Treatment Outcome	2000
Reboxetine-induced spontaneous ejaculation. The British journal of psychiatry : the journal of mental science, 2000, Volume: 177 Topics: Adult; Antidepressive Agents; Depressive Disorder; Ejaculation; Humans; Male; Morpholines; Reboxetine; Sexual Dysfunction, Physiological; Treatment Outcome	2000
Reboxetine treatment of depression in Parkinson's disease. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:11 Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder; Drug Administration Schedule; Female; Humans; Morpholines; Norepinephrine; Parkinson Disease; Reboxetine; Treatment Outcome	2000
Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and beta1-adrenergic receptors in an animal model of depression. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:10 Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Animals; Cerebral Cortex; Depressive Disorder; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Kynurenic Acid; Male; Morpholines; Neurons; Norepinephrine; Propanolamines; Rats; Rats, Sprague-Dawley; Reboxetine; Receptors, Adrenergic, beta-1; Receptors, N-Methyl-D-Aspartate; Serotonin; Sertraline	2000
Successful treatment of recurrent brief depression with reboxetine -- a single case analysis. Pharmacopsychiatry, 2002, Volume: 35, Issue:2 Topics: Adult; Antidepressive Agents; Depressive Disorder; Female; Humans; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Secondary Prevention	2002